In general , markers for cholesterol absorption and synthesis displayed reciprocal patterns , showing that cholesterol metabolism is tightly regulated by the interplay of intestinal absorption and endogenous synthesis .
Distinctive patterns for cholesterol absorption or cholesterol synthesis could be identified , suggesting that metabolic disorders can be classified as ' cholesterol absorbers or cholesterol synthesizers ' .
Non-cholesterol sterols are vali date d biomarkers for intestinal cholesterol absorption and endogenous cholesterol synthesis .
However , their use in metabolic disturbances has not been systematic ally explored .
Therefore , we conducted a systematic review to provide an overview of non-cholesterol sterols as markers for cholesterol metabolism in different metabolic disorders .
The lipid-lowering effect of ezetimibe in pure vegetarians Published, JLR Papers in Press, September 11, 2006.
Results of previous studies have shown that ezetimibe ( 10 mg/day ) reduces LDL cholesterol in patients with mild hypercholesterolemia on a normal-cholesterol diet ( dietary intake of 200–500 mg/day ) by 16–22 % . However , the LDL cholesterol-lowering effect of ezetimibe in subjects with an extremely low dietary cholesterol intake ( vegetarians ) has not been studied . We conducted a r and omized , double-blind , placebo-controlled , two-phase crossover study in 18 healthy pure vegetarians to assess the effect of ezetimibe ( 10 mg/day ) on plasma lipids , cholesterol absorption , and its synthesis . Treatment periods lasted 2 weeks each , with an intervening 2 week washout period . Fractional cholesterol absorption was determined using the continuous dual stable isotope feeding method . Mean dietary cholesterol intake in the pure vegetarians was extremely low and averaged 29.4 ± 16.8 and 31.4 ± 14.4 mg/day during the placebo and ezetimibe administration phases , respectively . Fractional cholesterol absorption during the placebo phase was 48.2 ± 8.2 % and was decreased by 58 % during ezetimibe treatment to 20.2 ± 6.2 % ( P < 0.001 ) . This change in intestinal cholesterol absorption was followed by a significant reduction in LDL cholesterol of 17.3 % . In individuals with extremely low dietary cholesterol intake , treatment with ezetimibe ( 10 mg/day ) leads to a significant reduction of cholesterol absorption and a clinical ly relevant decrease of plasma LDL cholesterol , comparable to that of subjects with a normal dietary cholesterol intake . Thus , the lipid-lowering effect of ezetimibe is mediated mainly through a reduction of the absorption of endogenous ( biliary ) cholesterol
In general , markers for cholesterol absorption and synthesis displayed reciprocal patterns , showing that cholesterol metabolism is tightly regulated by the interplay of intestinal absorption and endogenous synthesis .
Distinctive patterns for cholesterol absorption or cholesterol synthesis could be identified , suggesting that metabolic disorders can be classified as ' cholesterol absorbers or cholesterol synthesizers ' .
Non-cholesterol sterols are vali date d biomarkers for intestinal cholesterol absorption and endogenous cholesterol synthesis .
However , their use in metabolic disturbances has not been systematic ally explored .
Therefore , we conducted a systematic review to provide an overview of non-cholesterol sterols as markers for cholesterol metabolism in different metabolic disorders .